Original Article
Health problems are more common, but less severe when measured using newer EQ-5D versions

https://doi.org/10.1016/j.jclinepi.2013.07.011Get rights and content

Abstract

Objectives

The EuroQol Group recently released youth (Y) and 5-level (5L) versions of its 3-level EQ-5D instrument (3L) that measures health-related quality of life. In this study, we (1) compare 3L, Y, and 5L responses among US adults and (2) assess construct validity.

Study Design and Setting

Using a nationally representative sample of US adults (N = 2,619), we collected 3L, Y, and 5L responses in random order and estimated their associations and their relationship with a 0 to 100 numerical visual analog scale.

Results

The prevalence of US adults in the best possible EQ-5D state (i.e., 11111) was lower for the Y (38%) and 5L (35%) than for the 3L (44%), capturing more health problems. However, the prevalence of extreme responses in pain/discomfort and anxiety/depression decreased substantially between the 3L and 5L (from 44% to 17% and from 29% to 13%, respectively).

Conclusion

Compared with the 3L, the Y and 5L versions describe population health as having more, yet milder, health problems. Although the 5L may have advantages in patient populations in which extreme problems are more prevalent, population studies or studies that follow patients from childhood may consider using the Y.

Introduction

What is new?

  • Using a nationally representative sample of US adults, we found that the EQ-5D Y and 5L slightly reduced the prevalence of the best possible EQ-5D responses, mitigating the ceiling effect in the 3L.

  • Using a nationally representative sample of US adults, we found that the EQ-5D Y and 5L reduced the prevalence of the worst possible Pain/Discomfort and Anxiety/Depression responses, mitigating the floor effect in the 3L.

  • In comparison to the 3L and 5L, the Y did surprisingly well by mitigating ceiling effects, addressing issues with level descriptions, and predicting overall health. While it was designed for pediatric populations and may not capture extreme health problems as well as the 5L, this evidence suggests that it may substitute for the 3L when surveying across ages and literacy levels or in longitudinal studies that start in childhood.

Measures of general health based on self-reported losses in health-related quality of life (HRQoL) provide a holistic approach to evaluate treatment effectiveness and to make comparisons across clinical populations. For this purpose, short-form patient-reported outcome (PRO) instruments (often with less than a dozen items) have been developed for use across multiple disease areas, minimizing response burden. Although long-form and disease-specific PRO instruments have advantages in terms of their reliability, short-form instruments (e.g., 1 item per domain) provide a broad-based measure of respondent health.

The EQ-5D is a generic measure of HRQoL that has been widely used in clinical and economic evaluations of health care and to capture the health of populations [1]. The measure is composed of a simple descriptive profile that may be converted into a single summary index (EQ-5D index) and a visual analog scale (VAS). The measure is designed for self-completion, has a low respondent burden, and has been administered using a variety of modalities (e.g., postal surveys).

Widely used in adult populations, the EQ-5D 3-level version (EQ-5D-3L) has been translated into more than 150 languages. The EQ-5D-3L descriptive system consists of five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with each dimension having three levels (no problems, some problems, and extreme problems; Table 1). In an effort to improve the appropriateness of the EQ-5D in children, adolescents, and low-literacy populations [2], a youth version of the EQ-5D (EQ-5D-Y)—a modified but similar version of the EQ-5D—was constructed and examined through cognitive interviews [3]. With its simplified wording (e.g., “a lot” vs. “extremely”; Table 1), the adjectival scales of the EQ-5D-Y may mitigate ceiling effects of the EQ-5D-3L, particularly among less-educated adults. A multinational study concluded that the EQ-5D-Y was a feasible, reliable, and valid instrument to measure HRQoL in children and adolescents but cautioned that the measure needed further testing in adult and clinical populations [4].

In addition to the EQ-5D-Y, a 5-level version of the EQ-5D (EQ-5D-5L) was recently developed to improve on the measurement properties of the EQ-5D-3L, namely ceiling effects in the general population [5] and in a few clinical conditions [6]. By adding two levels (slight problems and severe problems) to the existing three levels, the 5-level version was designed to have not only reduced ceiling effects but also greater reliability and discriminatory power. On finalizing the labels for the 5L descriptive system [7], a multicountry study generated evidence on the improved properties of the EQ-5D-5L compared with the EQ-5D-3L [8]. However, at present, no population study has simultaneously administered and compared the properties of the descriptive systems for the 3L, Y, and 5L.

For this study, we conducted a nationally representative survey of adults in the United States and examined the prevalence of the 3L, Y, and 5L responses. These results provide a general benchmark for the interpretation of EQ-5D responses across instruments. Furthermore, we assessed the external validity of these three instruments by estimating their relationship with a 0 to 100 numerical VAS. This study was designed to characterize general health in the United States and to inform researchers about the implications of their decision to use a given EQ instrument (3L, Y, or 5L). We hypothesized that the 5L and Y would perform better than the 3L in terms of discriminative ability and proportion of respondents susceptible to ceiling effects.

Section snippets

Health outcomes

As shown in Table 1, each item in the 3L and Y captures two potential losses in HRQoL (i.e., graded responses: 1–2 and 2–3), totaling up to 10 losses (5 × 2). The 5-level version is potentially more descriptive in that each item captures four possible losses (1–2, 2–3, 3–4, and 4–5), totaling up to 20 losses (5 × 4). For the 3L, Y, and 5L, the best possible health state is characterized by the absence of losses (i.e., level 1 on each item, 11111). The worst possible health state is

Results

Between August 7, 2012 and August 23, 2012, 5,978 respondents were recruited for this study. One hundred (2%) did not consent, 777 (13%) dropped out during the screener, and 2,221 (37%) were terminated based on study criteria, including over quota. Among the 2,877 qualifying respondents, 2,614 (91%) completed the three EQ-5D instruments and VAS. Incomplete responses (Table 2) were associated with Hispanic ethnicity and household income—particularly households earning less than $15,000/year. By

Conclusions

Using a nationally representative sample of US adults, we found that the Y and 5L slightly reduced the prevalence of the best possible EQ-5D state, mitigating the ceiling effect in the 3L. However, the use of the 5L instead of the 3L reduced the prevalence of moderate to extreme health problems by more than half, particularly pain/discomfort and anxiety/depression. Although item level descriptions (e.g., “confined to bed” vs. “unable to walking about”) appear to have altered the association

Acknowledgments

The authors thank Michelle Owens (survey coordination) and Carol Templeton (copyediting) at Lee H. Moffitt Cancer Center & Research Institute for their contributions to the research and creation of this article.

References (14)

  • M. Bharmal et al.

    Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population

    Value Health

    (2006)
  • EuroQol—a new facility for the measurement of health-related quality of life

    Health Policy

    (1990)
  • K. Burstrom et al.

    A Swedish child-friendly pilot version of the EQ-5D instrument—the development process

    Eur J Public Health

    (2011)
  • N. Wille et al.

    Development of the EQ-5D-Y: a child-friendly version of the EQ-5D

    Qual Life Res

    (2010)
  • U. Ravens-Sieberer et al.

    Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study

    Qual Life Res

    (2010)
  • J. Brazier et al.

    A comparison of the EQ-5D and SF-6D across seven patient groups

    Health Econ

    (2004)
  • M. Herdman et al.

    Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

    Qual Life Res

    (2011)
There are more references available in the full text version of this article.

Cited by (57)

  • Comparing Measurement Properties of the English EQ-5D-Y 3-Level Version With the 5-Level Version in South Africa

    2022, Value in Health Regional Issues
    Citation Excerpt :

    Since the development of the Y-3L, the adult version has expanded its levels of report from 3 to 5.3,4 Expanding the response option on the adult EQ-5D improved the discriminatory power in general and patient populations with decreased ceiling effect.4-7 Thus, the response options of the youth version were recently expanded to 5 levels resulting in the EQ-5D-Y 5-level (5L) version (Y-5L).8

  • Quality of life and procrastination in post-H1N1 narcolepsy, sporadic narcolepsy and idiopathic hypersomnia, a Swedish cross-sectional study

    2020, Sleep Medicine
    Citation Excerpt :

    Many of the HRQoL-studies performed on patients with narcolepsy have used the Short Form (36) Health Survey (SF-36), whereas EQ-5D has been used in three previous studies, where one study used the original EQ-5D-3L [2], using three levels of responses and one only used the EQ-5D VAS [46]. One study used the five-level instrument (EQ-5D-5L) [39] that was also used in the present study, with which the population can be described as having more, yet milder, health problems [47] than in EQ-5D-3L. The average EQ-5D VAS evaluation in the present study was 57.3 ± 21.1 and 66.3 ± 21.0 for NT1 w/wo H1N1 vaccination and 64.4 ± 21.8 in IH, compared to 61 [2], 71 [39] and 57 [46] in previous studies.

View all citing articles on Scopus

Financial disclosure: Funding support for this research was provided by R01-CA160104 to B.M.C., HRQoL Values for Cancer Survivors: Enhancing PROMIS Measures for Comparative Effectiveness Research (CER). In addition, all persons in the acknowledgments have given their written permission to be named in the manuscript.

Conflict of interest: The authors have no conflicts of interest.

View full text